Abstract PO3-13-09: Personalized ctDNA testing for detection of molecular residual disease in patients with localized HR+ breast cancer: temporal dynamics and impact on clinical outcomes
Arielle J. Medford(Harvard University), Aditya Bardia(Harvard University), Rachel O. Abelman(Massachusetts General Hospital), Beverly Moy(Massachusetts General Hospital), Laura M. Spring(Massachusetts General Hospital), Yael Bar(Massachusetts General Hospital), Minetta C. Liu(Mayo Clinic), Amy Comander(Harvard University), Elyssa N. Denault(Massachusetts General Hospital), Zanta Ephrem(Massachusetts General Hospital), J. T. A. Knape(Massachusetts General Hospital), Douglas S. Micalizzi(University of Colorado Denver), Angel Rodríguez(Natera (United States)), Steven J. Isakoff(Harvard University)
Cited by 1
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression
|Journal of Mammary Gland Biology and Neoplasia|2010|972